# Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

> **NCT03879694** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Lung Atypical Carcinoid Tumor
- Lung Typical Carcinoid Tumor
- Metastatic Pancreatic Neuroendocrine Tumor

## Interventions

- **BIOLOGICAL:** Incomplete Freund's Adjuvant
- **DRUG:** Octreotide Acetate
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** SVN53-67/M57-KLH Peptide Vaccine

## Key facts

- **NCT ID:** NCT03879694
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2025-02-15
- **Final completion:** 2025-03-14
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879694, "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03879694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*